Risk Factors and Consequences of Lower Extremity Fracture Nonunions in Veterans With Spinal Cord Injury

Bridget Sinnott,1 Cara Ray,2 Frances Weaver,2,3 Beverly Gonzalez,2,4,5,6 Elizabeth Chu,7 Sarah Premji,7 Mattie Raiford,7 Rachel Elam,1,7 Bridget Sinnott,1 Cara Ray,2 Frances Weaver,2,3 Beverly Gonzalez,2,4,5,6 Elizabeth Chu,7 Sarah Premji,7

1Charlie Norwood Veterans Affairs Medical Center, Augusta, GA, USA
2Center of Innovation for Complex Chronic Healthcare (CINCCH), Health Services Research & Development, Department of Veterans Affairs, Hines VA Hospital, Hines, IL, USA
3Parkinson School of Health Sciences and Public Health, Loyola University, Maywood, IL, USA
4Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
5Department of Biostatistics, University of Illinois, Chicago, IL, USA
6Department of Mathematics, Northeastern Illinois University, Chicago, IL, USA
7Division of Rheumatology, Medical College of Georgia, Augusta University, Augusta, GA, USA
8Department of Orthopaedic Surgery, Medical College of Georgia, Augusta University, Augusta, GA, USA

ABSTRACT
We used Veterans Health Administration (VHA) national administrative data files to identify a cohort (fiscal years 2005–2014) of veterans with spinal cord injuries and disorders (SCID) to determine risk factors for and consequences of lower extremity fracture nonunions. Odds ratios (OR) for fracture nonunion were computed using multivariable-adjusted logistic regression models. We identified three risk factors for nonunion: (i) older age (OR = 2.29; 95% confidence interval [CI] 1.21–4.33), (ii) longer duration of SCID (OR = 1.02; 95% CI 1.00–1.04), and (iii) fracture site (distal femur), with OR (comparison distal femur) including distal tibia/fibula (OR = 0.14; 95% CI 0.09–0.24), proximal tibia/fibula (OR = 0.19; 95% CI 0.09–0.38), proximal femur (OR = 0.10; 95% CI 0.04–0.21), and hip (OR = 0.13; 95% CI 0.07–0.26). Nonunions resulted in multiple complications, with upwards of 1/3 developing a pressure injury, 13% osteomyelitis, and almost 25% requiring a subsequent amputation. Our data have identified a high-risk population for fracture nonunion of older veterans with a long duration of SCID who sustain a distal femur fracture. In view of the serious complications of these nonunions, targeted interventions in these high-risk individuals who have any signs of delayed union should be considered. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. This article has been contributed to by US Government employees and their work is in the public domain in the USA.

KEY WORDS: FEMUR FRACTURES; FRACTURE NONUNION; FRACTURE-RELATED COMPLICATIONS; SPINAL CORD INJURY AND DISORDERS

1. Introduction

Fractures are a common secondary condition for persons with a chronic spinal cord injury (hereafter referred to as spinal cord injury/disorder, or SCID), with an incident rate of 2% to 3% per year.1,2 A significant subset of patients with lower extremity fractures develop post-fracture complications, including pressure injuries, autonomic dysreflexia, pain, muscle spasms, heterotopic ossification, and nonunion.3 Fracture nonunion rates in persons with a SCID approximate 16.0%.4 Fracture nonunions are complicated pathophysiological processes that are ultimately related to problems in the biologic and mechanical environment at the fracture site.5 Prior studies of risk factors for fracture nonunion in persons with a SCID are limited by small sample sizes.4 In one report of persons with a SCID of 1 year or greater duration, fracture nonunions/delayed unions accounted for 25% of all reported post-fracture medical complications.3 In one series of cases from Germany, fracture location (proximal femur compared with tibia), fracture management (conservative [nonoperative] compared with operative treatment), and longer duration of SCID were risk factors for fracture nonunion.4 The relationship of type of acute fracture treatment (nonoperative versus operative) to fracture nonunion is important because, in contrast with the able-bodied population in whom management of major lower extremity fractures is almost always done operatively, treatment for lower extremity fractures...
2. Patients and Methods

Persons with a SCID were identified from the 2016 Veterans Health Administration (VHA) Allocation Resource Center (ARC) list based on ICD-9 codes for a SCID and treatment in either a SCID bed section and/or SCID outpatient clinic. ARC is a cumulative list of veterans who have ever received healthcare from a VHA facility. The ARC list was combined with healthcare utilization data from the VHA’s Corporate Data Warehouse (CDW), which includes patient demographics, inpatient, outpatient, and pharmacy data. To determine SCID-specific variables, the ARC list was linked to the VA Spinal Cord Dysfunction (SCD) Registry, and/or the SCID Outcomes Database (SCIDO). The SCD Registry was an administrative database that included veterans with SCID who received care at a VHA medical facility and was used to track the population of veterans with SCID followed by each SCID Center. The SCIDO Registry continued the SCD Registry purpose; however, SCIDO also allowed clinical patient outcome data to be included. The SCD and SCIDO historical data are archived in the VHA Enterprise virtual environment. These historical data sets include information about etiology, date of onset, level of injury, completeness of injury, and the veteran’s healthcare.

Incident lower extremity fractures (International Classification of Diseases, Ninth Revision [ICD-9] codes [820–829, 733.14, 15, 16,733.19, and 733.10]) that occurred between fiscal years 2005–2014 were identified from national VA administrative files containing utilization and diagnosis data. A fracture was considered incident if there were no encounters with the same ICD-9 code within a 120-day time period before the identified fracture. Prospective fracture nonunion cases were identified through administrative records by an ICD-9 code of 733.82.

Nonunions coded in the 12-month time period after the date of an incident fracture were then further examined by electronic health record (eHR) review. These records were reviewed by three physicians and two medical student extractors in a systematic fashion using a data extraction tool developed and finalized with consensus among all authors. A fracture nonunion was considered present if there was an ICD-9 code for a fracture nonunion, a radiograph documenting lack of complete healing, and a clinical note documenting fracture nonunion. Cases without such documentation were excluded, as were those with an ICD-9 code for nonunion and malunion on the same day. Controls were defined as those with an incident lower extremity fracture with an ICD-9 code (820–826) with no history of a nonunion or malunion. We selected the first such incident lower extremity fracture within the data set for use in these analyses. Cases and/or controls with a date of SCID onset that was missing or after the date of incident fracture were excluded.

2.1 Predictors of fracture nonunion

Potential predictors of fracture nonunion considered included patient-level characteristics (age, race, sex, body mass index [BMI]); comorbidities including diabetes mellitus, chronic kidney disease, and peripheral vascular disease; use (bisphosphonates, anticonvulsants, benzodiazepines, opioids, antidepressants, corticosteroids, and anticoagulants); SCID-related characteristics (etiology, duration, level, and extent of injury), fracture site, and type of fracture (open or closed) were also considered. Patient and SCID injury level characteristics were assessed from the first time of entry into the study cohort. Comorbidities or filled medications identified during the study period at the time of or before the fracture were considered as present.

Primary treatment for the fracture was considered operative for controls if there was an ICD-9 and a CPT code indicating an operative treatment of a fracture within 30 days of the incident fracture. Primary treatment for the fracture was considered operative for cases if eHR review identified an operative treatment within 30 days of the incident fracture resulting in nonunion. Otherwise, the treatment was considered nonoperative.

2.2 Complications of fracture nonunion

Complications of fracture nonunion in the first 12 months after the fracture, including pressure injuries, osteomyelitis, thrombotic events, and amputations on the same extremity as the fracture site, were identified. Only pressure injuries, osteomyelitis, and amputations that occurred at or near the fracture site were included, as determined by eHR review.

2.3 Treatments for fracture nonunion

Treatments for fracture nonunion, including pulsed electromagnetic fields and ultrasound, growth factors, bone stimulators, and medications (teriparatide, abaloparatide) were recorded. Whether the fracture nonunion required surgical treatment with new or revised hardware, amputations, and/or bone grafts also was identified.

2.4 Statistical analysis

Baseline characteristics of the study population including age (≥50 vs. <50 years), race, sex, BMI (underweight, normal, overweight, and obese), comorbidities (diabetes, chronic kidney disease, peripheral vascular disease [PVD]), receipt of any prescriptions for anticonvulsants, benzodiazepines, opioids, antidepressants, anticoagulants, corticosteroids, or bisphosphonates, etiology of SCID injury (traumatic or nontraumatic), level of injury (paraplegia or tetraplegia), extent of injury (complete or
incomplete), ASIA impairment scale, duration of SCID, initial treatment of fracture (operative or nonoperative), site of fracture (hip, proximal femur, distal femur, proximal tibia/fibula, or distal tibia/fibula), type of fracture (open or closed), and by whether a patient developed a fracture nonunion were examined using Pearson’s chi-square statistic or t test when appropriate at a level of significance set to $\alpha = 0.05$. To account for multiple comparisons, a Bonferroni adjustment with adjusted $\alpha = 0.003$ was considered significant.

Odds ratios (ORs) with their 95% confidence intervals (CIs) were used as the measures of association for these analyses. ORs and 95% CIs for fracture nonunion and for baseline demographics, clinical, SCID, and fracture-related factors were estimated via a multivariable logistic regression model.

A “missing” category was created for variables in which there were missing values to retain as many observations in the analyses as possible. Because small numbers of missing fracture type (open or closed) caused problems with the logistic regression model convergence, these were imputed as closed and then open fractures.

In previous work, we determined that femur fractures were commonly managed with surgery as the initial fracture treatment. Thus, to mitigate confounding that might occur in the relationship between fracture treatments and nonunion if fracture site were included, in separate multivariate logistic regression models, we excluded fracture site.

Statistical analyses were conducted using SAS release 9.4 (SAS Institute, Cary, NC, USA) with two-sided $p$ values reported.

The VA Institutional Review Boards at the Charlie Norwood VA Hospital, Augusta, GA, and the Hines VA Hospital, Hines, IL, approved the study.

### 3. Results

Over the up to 10-year time period of these analyses, there were 106 persons with at least one lower extremity fracture nonunion. All fracture nonunions occurred at the hip, femur, ankle, or tibia/fibula. Accordingly, among all eligible controls, we selected only those with an incident hip, femur, ankle, or tibia/fibula fracture. Full details regarding cohort selection and inclusion/exclusion criteria are available in Fig. 1 A for cases and Fig. 1 B for controls. Because the number of veterans with ankle fractures was small, ankle fractures were included with distal tibia/fibula fractures in the analyses to ensure model convergence.

Baseline characteristics of the study population with lower extremity fractures by fracture nonunion status are shown in Table 1. Persons with a fracture nonunion were more likely to be older ($p = 0.0001$), use bisphosphonates ($p = 0.0262$), have a longer duration of SCID ($p = 0.0261$), and, in sensitivity analyses in which fractures of unknown type were categorized with open fractures, to have an open fracture ($p < 0.0001$). Distal femur

---

**Fig. 1.** (A) Flow diagram of study cases. (B) Flow diagram of study controls.
Table 1. Baseline Characteristics of Subset of Study Population with Fracture Nonunion

| Patient characteristics                        | Patients without fracture nonunion (n = 1746) | Patients with fracture nonunion (n = 106) | p Value$^a$ |
|------------------------------------------------|---------------------------------------------|------------------------------------------|-------------|
| **Clinical characteristics**                   |                                             |                                          |             |
| Age (years), mean ± SD                         | 57.45 ± 12.67                               | 61.91 ± 12.01                            | 0.0004$^b$ |
| Race, n (%)                                     |                                             |                                          | 0.7436$^c$ |
| White                                          | 1228 (70.33)                                | 75 (70.75)                               |             |
| Black                                          | 327 (18.73)                                 | 17 (16.04)                               |             |
| Other                                          | 42 (2.41)                                   | 4 (3.77)                                 |             |
| Missing                                        | 149 (8.53)                                  | 10 (9.43)                                |             |
| Sex, n (%)                                     |                                             |                                          | 0.2768$^c$ |
| Male                                           | 1670 (95.65)                                | 99 (93.4)                                |             |
| Female                                         | 34 (4.35)                                   | 7 (6.6)                                  |             |
| Body mass index, n (%)                         |                                             |                                          | 0.1738$^c$ |
| Underweight                                    | 109 (6.24)                                  | 2 (1.89)                                 |             |
| Normal                                         | 634 (36.31)                                 | 38 (35.85)                               |             |
| Overweight                                     | 587 (33.62)                                 | 35 (33.02)                               |             |
| Obese                                          | 247 (15.9)                                  | 31 (29.25)                               |             |
| Missing                                        | 21 (1.2)                                    | 0 (0)                                    |             |
| Comorbidities, n (%)                           |                                             |                                          | 0.3651$^c$ |
| Diabetes mellitus                              | 426 (24.40)                                 | 30 (28.3)                                | 0.9516$^c$ |
| Chronic kidney disease                         | 129 (7.39)                                  | 8 (7.55)                                 | 0.3574$^c$ |
| Peripheral vascular disease                    | 196 (11.23)                                 | 15 (14.15)                               |             |
| Medication use, n (%)                          |                                             |                                          |             |
| Bisphosphonates                                 | 152 (8.71)                                  | 16 (15.09)                               | 0.0262$^c$ |
| Anticonvulsants                                 | 777 (44.5)                                  | 51 (48.11)                               | 0.4678$^c$ |
| Benzodiazepines                                 | 848 (48.57)                                 | 56 (52.83)                               | 0.3940$^c$ |
| Opioids                                        | 1196 (68.5)                                 | 73 (68.87)                               | 0.9368$^c$ |
| Corticosteroids                                 | 230 (13.17)                                 | 14 (13.21)                               | 0.9918$^c$ |
| Antidepressants                                 | 940 (53.84)                                 | 58 (54.72)                               | 0.8600$^c$ |
| Anticoagulants                                  | 273 (15.64)                                 | 24 (22.64)                               | 0.0563$^c$ |
| SCI-related characteristics                    |                                             |                                          |             |
| Etiology of injury, n (%)                      |                                             |                                          | 0.0546$^c$ |
| Traumatic                                      | 1239 (70.96)                                | 75 (70.75)                               |             |
| Non-traumatic                                   | 470 (26.92)                                 | 25 (25.58)                               |             |
| Missing                                        | 37 (2.12)                                   | 6 (5.66)                                 |             |
| Level of injury, n (%)                         |                                             |                                          | 0.1708$^c$ |
| Paraplegia                                     | 911 (52.18)                                 | 62 (60.78)                               |             |
| Tetraplegia                                    | 799 (45.76)                                 | 40 (39.22)                               |             |
| Missing                                        | 36 (2.06)                                   | 4 (3.77)                                 |             |
| Extent of injury, n (%)                        |                                             |                                          | 0.1909$^c$ |
| Complete                                       | 818 (46.85)                                 | 58 (54.72)                               |             |
| Incomplete                                     | 696 (39.86)                                 | 39 (36.79)                               |             |
| Missing                                        | 232 (13.29)                                 | 9 (8.49)                                 |             |
| ASIA impairment scale                          |                                             |                                          | 0.0608$^c$ |
| A                                              | 509 (29.15)                                 | 41 (38.68)                               |             |
| B                                              | 122 (6.99)                                  | 8 (7.55)                                 |             |
| C                                              | 116 (6.64)                                  | 11 (10.38)                               |             |
| D                                              | 200 (11.45)                                 | 7 (6.6)                                  |             |
| Missing                                        | 799 (45.76)                                 | 39 (36.79)                               |             |
| Duration of SCID, mean ± SD                    | 19.71 ± 14.55                               | 23.46 ± 15.60                            | 0.0103$^b$ |
| Fracture-related characteristics               |                                             |                                          |             |
| Primary fracture treatment, n (%)              |                                             |                                          |             |
| Surgical                                       | 168 (9.62)                                  | 14 (13.21)                               | 0.2286$^c$ |
| Non-surgical                                   | 1578 (90.38)                                | 92 (86.79)                               |             |
| Fracture site, n (%)                           |                                             |                                          | <0.0001$^c$ |
| Distal tibia/fibula                            | 769 (44.04)                                 | 28 (26.42)                               |             |
| Proximal tibia/fibula                          | 187 (10.71)                                 | 9 (8.49)                                 |             |
| Distal femur                                    | 171 (9.79)                                  | 49 (46.23)                               |             |
| Proximal femur                                  | 275 (15.75)                                 | 7 (6.60)                                 |             |
| Hip                                            | 260 (22.73)                                 | 13 (12.26)                               |             |

(Continues)
Table 1. continued

| Patient characteristics | Patients without fracture nonunion (n = 1746) | Patients with fracture nonunion (n = 106) | p Value<sup>a</sup> |
|-------------------------|-----------------------------------------------|------------------------------------------|---------------------|
| Fracture type; unknown type categorized as closed, n (%) |                                |                                         | 0.4640<sup>c</sup> |
| Closed                 | 1714 (98.17)                                 | 103 (97.17)                              |                     |
| Open                   | 32 (1.83)                                    | 3 (2.83)                                 |                     |
| Fracture type; unknown type categorized as open, n (%) |                                |                                         | <0.0001<sup>c</sup> |
| Closed                 | 1714 (98.17)                                 | 96 (90.57)                               |                     |
| Open                   | 32 (1.83)                                    | 10 (9.43)                                |                     |

ASIA = American Spinal Injury Association Impairment Scale; SCID = spinal cord injuries and disorders.
<sup>a</sup>Bolded p values indicate the result was significant at the 0.05 level.
<sup>b</sup>Two-sample t test.
<sup>c</sup>Pearson’s chi-square.

Table 2. Predictors of Fracture Nonunion in Those With Lower Extremity Fractures

| Predictors | Univariate               | Multivariate          |
|------------|--------------------------|------------------------|
|            | OR (95% CI)              | OR (95% CI)            |
| Clinical characteristics |                                |                        |
| Age (≥50 versus <50 years) | 2.23 (1.23–4.08) | 2.29 (1.21–4.33) |
| Race   | Black versus white 0.87 (0.51–1.48) | 0.95 (0.54–1.67) |
|       | Other versus white 1.72 (0.63–4.73) | 1.63 (0.55–4.84) |
| Sex (female versus male) | 1.65 (0.75–3.59) | 1.99 (0.82–4.88) |
| BMI (normal versus underweight) | 2.66 (0.72–9.75) | 2.51 (0.69–9.10) |
| BMI (overweight versus underweight) | 2.65 (0.72–9.74) | 2.58 (0.71–9.44) |
| BMI (obese versus underweight) | 3.49 (0.94–12.93) | 3.68 (0.99–13.74) |
| Diabetes mellitus (yes versus no) | 1.23 (0.80–1.91) | 0.90 (0.55–1.48) |
| Chronic kidney disease (yes versus no) | 1.08 (0.52–2.23) | 1.00 (0.46–2.17) |
| Peripheral vascular disease (yes versus no) | 1.34 (0.76–2.34) | 1.02 (0.56–1.86) |
| Anticonvulsants (yes versus no) | 1.16 (0.78–1.71) | 1.09 (0.69–1.73) |
| Benzodiazepines (yes versus no) | 1.19 (0.80–1.75) | 1.05 (0.68–1.62) |
| Opioids (yes versus no) | 1.01 (0.66–1.54) | 1.05 (0.64–1.71) |
| Antidepressants (yes versus no) | 1.03 (0.70–1.53) | 0.84 (0.53–1.34) |
| Anticoagulants (yes versus no) | 1.60 (1.00–2.56) | 1.46 (0.88–2.42) |
| Corticosteroids (yes versus no) | 1.03 (0.58–1.83) | 0.95 (0.52–1.74) |
| Bisphosphonates (yes versus no) | 1.91 (1.10–3.31) | 1.46 (0.80–2.66) |
| SCID-related characteristics |                                |                        |
| Etiology (nontraumatic versus traumatic) | 0.89 (0.56–1.41) | 1.00 (0.59–1.70) |
| SCI level (tetraplegia versus paraplegia) | 0.74 (0.49–1.11) | 0.91 (0.59–1.40) |
| SCI extent (incomplete versus complete) | 0.79 (0.52–1.20) | 1.05 (0.51–2.15) |
| ASIA Impairment Scale |                                |                        |
| B versus A | 0.85 (0.40–1.83) | 1.23 (0.44–3.45) |
| C versus A | 1.21 (0.61–2.41) | 1.50 (0.55–4.06) |
| D versus A | 0.46 (0.21–1.02) | 0.74 (0.26–2.10) |
| Missing versus A | 0.61 (0.39–0.95) | 0.75 (0.42–1.33) |
| Duration of SCID | 1.02 (1.00–1.03) | 1.02 (1.00–1.04) |
| Fracture-related characteristics |                                |                        |
| Primary fracture treatment (operative versus nonoperative) | 1.47 (0.82–2.62) | 1.91 (1.02–3.57) |
| Fracture site |                                |                        |
| Distal tibia/fibula versus distal femur | 0.13 (0.08–0.21) | 0.14 (0.09–0.24) |
| Proximal tibia/fibula versus distal femur | 0.18 (0.09–0.36) | 0.19 (0.09–0.38) |
| Proximal femur versus distal femur | 0.09 (0.04–0.21) | 0.10 (0.04–0.21) |
| Hip versus distal femur | 0.14 (0.07–0.26) | 0.13 (0.07–0.26) |
| Type of fracture (open versus closed)<sup>a</sup> | 1.78 (0.57–5.55) | 2.23 (0.67–7.43) |

Note: Bolded odds ratio estimates and confidence intervals indicate the result was significant at the 0.05 level.
BMI = body mass index; SCID = spinal cord injuries and disorders; ASIA = American Spinal Injury Association Impairment Scale.
<sup>a</sup>In the analyses detailed in this table, the 7 fractures that had unknown type (open versus closed), all of which came from those fractures resulting in nonunion, were assumed to be closed fractures.
In prespecified multivariate logistic regression models with fracture site excluded (to mitigate confounding between fracture site and initial fracture management), there was no significant relationship between type of primary fracture management and fracture nonunion (OR = 1.62; 95% CI 0.90–2.87).

Fracture nonunions resulted in a number of complications, with close to one-third having a pressure injury, almost 25% resulting in a subsequent amputation, and approximately 13% with osteomyelitis (Table 3).

The most common treatment for a fracture nonunion was surgical, most frequently with new hardware. A bone stimulator was used for some nonunions (16%); pulsed electromagnetic field therapy (PEMF) was used for approximately 10% of fracture nonunions, and ultrasonography was used for approximately 6%. Bone grafts and biologics were rarely used and anabolic therapies were not used at all (Table 4).

### 4. Discussion

In veterans with a SCID, older age and longer duration of SCID were significantly associated with a fracture nonunion after a lower extremity fracture. Compared with other common lower extremity locations (ie, hip, tibia/fibula), fractures of the distal femur were most likely to incur a nonunion. Initial management of the fracture (operative versus nonoperative) was not significantly related to the development of a fracture nonunion in multivariate analyses that excluded fracture site; excluding fracture site in analyses addressing fracture management was necessary to mitigate confounding that might occur in the relationship between fracture management and nonunion by fracture site. Type of fracture (open versus closed) was not a significant risk factor for nonunion in analyses assuming those fractures with missing type were closed fractures.

Complications, most commonly pressure injuries, were frequent after fracture nonunions, with approximately one-third of nonunions resulting in at least one complication. Surgery, including new or revised hardware, was the most common treatment for the nonunion. Bone stimulators were rarely used to treat fracture nonunions and anabolic therapies were not used at all.

There are very few published reports examining fracture nonunions in persons with a SCID and, to our knowledge, only one that has specifically examined risk factors. In agreement with this prior study, we found that longer duration of SCID was a risk factor for fracture nonunion. However, in contrast with this report, we found that older age was a significant risk factor for fracture nonunion and type of fracture treatment (operative versus nonoperative) was not.

To our knowledge, this is the first report that has examined the relationship of medication use with fracture nonunion in persons with a SCID and found no significant association of any medication examined, including anticoagulants, opioids, anticonvulsants, benzodiazepines, or antidepressants with fracture nonunion. Warfarin and antidepressants, benzodiazepines, and anticonvulsants are frequently used by persons with a SCID and are significantly related to fracture risk in this population. That these medications were not predictive of nonunion suggests there is not a need to modify their use in postfracture care. This is in contrast with reports in the able-bodied

| Table 3. Complications of Lower Extremity Fracture Nonunions |
|--------------------------------------------------------------|
| Complications (n, %)                                         |
| Fracture nonunion (n = 106)                                  |
| Pressure injury                                             | 36 (33.96%) |
| Osteomyelitis                                               | 14 (13.21%) |
| Amputation                                                  | 25 (23.58%) |
| Thrombosis                                                  | 1 (0.94%)   |
| Other*                                                      | 5 (4.72%)   |

*Septic arthritis, localized osteopenia, myositis ossificans.

| Table 4. Treatments for Lower Extremity Fracture Nonunions |
|-----------------------------------------------------------|
| Fracture nonunion treatment (n, %)                        |
| Fracture nonunion (n = 106)                               |
| Surgery                                                   |
| New hardware                                             | 21 (19.81%) |
| Revision                                                 | 8 (7.55%)   |
| Bone graft                                                |             |
| Autografts                                                | 4 (3.77%)   |
| Allografts                                                | 1 (0.94%)   |
| Bone stimulator                                           |             |
| Orthofix or pulsed electromagnetic fields                 | 11 (10.38%) |
| Exon ultrasonography                                      | 6 (5.66%)   |
| Other                                                     | 0           |
| Biologics                                                 |
| Bone morphogenetic protein (BMP)                          | 1 (0.94%)   |
| Fibroblast growth factor 2 (FGF-2)                        | 0           |
| Platelet-derived growth factor (PDGF)                    | 0           |
| Medications                                               |
| Teriparatide                                              | 0           |
| Abaloparatide                                             | 0           |

Fractures were the most common fracture to sustain a nonunion (p < 0.0001).

The relationship among patient demographics, clinical and SCID-related characteristics, fracture treatment, site and type (open or closed) of fracture, and fracture treatment (operative versus nonoperative) were examined using logistic regression as risk factors for fracture nonunion. There were seven fractures of unknown type (open versus closed), all of which occurred in the nonunion cases. In multivariate analyses in which the seven fractures of unknown type were categorized as closed fractures, significant risk factors for fracture nonunion included older age (OR = 2.29; 95% CI 1.21–4.33), longer duration of SCID (OR = 1.02; 95% CI 1.00–1.04), and fracture site, such that fractures of sites other than the distal femur (reference comparator) were less likely to result in nonunion (distal tibia/fibula OR = 0.14; 95% CI 0.09–0.24, proximal tibia/fibula OR = 0.19; 95% CI 0.09–0.38, proximal femur OR = 0.10; 95% CI 0.04–0.21, hip OR = 0.13; 95% CI 0.07–0.26). In these multivariate analyses, operative initial fracture management was associated with fracture nonunion (OR = 1.91; 95% CI 1.02–3.57). In this analysis, there was a trend for open fractures to be significantly associated with fracture nonunion (OR = 2.23; 95% CI 0.67–7.43). These results from univariate and multivariate logistic regression are detailed in Table 2. Results were similar in analyses in which fractures of unknown type were categorized as open rather than closed, except that open fractures were now significantly associated with fracture nonunion (OR = 5.28; 95% CI 2.26–12.34).
population in which opioids, benzodiazepines, and anticonvulsants have been associated with fracture nonunion.\(^{[20,28,29]}\) These differences may be due to differences in the pathophysiology of sublesional compared with senile osteoporosis;\(^{[30,31]}\) alternatively, they may reflect differences in sites of fracture.\(^{[18,28]}\)

In the present series, filled prescriptions for bisphosphonates also were not associated with fracture nonunion. In the able-bodied population, the association of bisphosphonate use with fracture nonunion is controversial. Several observational studies have shown an increased risk of fracture nonunion after use of bisphosphonates.\(^{[20,29]}\) However, in agreement with our findings, a randomized controlled trial of alendronate use after osteoporotic distal radius fracture with volar plate fixation in the able-bodied population found no association between alendronate use and fracture union time.\(^{[32]}\) Other studies showed that mean union time for distal radius fractures is longer in those receiving bisphosphonates than controls but not in a clinically relevant amount\(^{[33]}\) and no prolongation of union time at all is found at lower extremity fractures sites of femur or tibia.\(^{[34]}\)

Bisphosphonates do not appear to delay fracture healing when initiated after the acute fracture, regardless of how soon after the fracture they are administered.\(^{[35,36]}\) As bisphosphonates are the most frequently prescribed osteoporosis medication in persons with a SCID, prescribed to more than two-thirds of veterans with SCID in one study,\(^{[37]}\) our study findings that prefracture bisphosphonate use was not associated with lower extremity fracture nonunion in SCID is reassuring. In support of this, a forthcoming CPG (PVA Consortium for Spinal Cord Medicine Clinical Practice Guidelines: Bone Health and Osteoporosis Management in Individuals with Spinal Cord Injury) suggests that one may consider initiation of osteoporosis treatment soon after fragility fracture (data not shown).

Lower extremity fractures in the VHA system of care in veterans with a SCID are most commonly managed conservatively (ie, nonoperatively), although this is changing, and surgical management of these fractures is increasing.\(^{[6]}\) In the present study, in contrast with a prior report in which surgical management of lower extremity fractures in non-veterans with a SCID was less likely than conservative treatment to result in a fracture nonunion,\(^{[4]}\) we found no significant association between primary treatment of the fracture and fracture nonunion. These differences may reflect the very low numbers of surgically treated fractures in our series (<10%) compared with the more than 60% managed surgically in Grasner’s report.\(^{[4]}\) In agreement with our findings, Trotzler and colleagues reported that the overall rate of post-fracture complications was similar in those treated conservatively versus surgically (15% and 13%, respectively); however, this report only included four fracture nonunions, two each in those treated surgically versus nonsurgically.\(^{[38]}\)

Complications after lower extremity fractures in persons with a SCID are common, with reported rates ranging from 14% to 54%. To our knowledge, ours is the first study that has reported complications specifically related to fracture nonunion in this population. That upwards of one-third of patients sustained a pressure injury is concerning because these can result in further functional disability, need for surgical intervention, and increased likelihood of life-threatening infections.\(^{[39]}\) A prospective study reported that pressure injuries requiring care were associated with an almost twofold increase risk of mortality.\(^{[40]}\) In the present study, osteomyelitis developed in 13% and limb amputations in 22% of fracture nonunions. In one series, osteomyelitis was among the most common indicators for a lower extremity amputation.\(^{[41]}\)

Lower extremity amputations are associated with significant functional impairment,\(^{[42]}\) major post-surgical complications and revision amputations,\(^{[43]}\) and increased mortality.\(^{[40]}\)

Fracture nonunion treatment in the able-bodied population begins with examining the subtype of nonunion.\(^{[44,45]}\) In support of our findings that operative treatment was the most common treatment used for fracture nonunions in persons with a SCID, operative treatment is typically recommended for fracture nonunions in the able-bodied population. In fractures of the tibia or femur shaft, this is often addressed by placing an intramedullary nail (IMN).\(^{[46,47]}\) In fractures previously treated with an IMN, it is possible to place a larger diameter IMN or to remove either the proximal or distal interlocking screws to create a dynamically locked nail instead of a statically locked nail.\(^{[47]}\) Approximately 16% of the fracture nonunions in the present study underwent treatment with a bone stimulator. Bone stimulators are used in the able-bodied population.\(^{[48]}\) Anabolics such as teriparatide have been used off-label to treat fracture nonunion in the able-bodied population;\(^{[49]}\) however, there was no use of these in this SCID series. This may reflect the fact that hypercalcemia and hypercalcioria, both potential side effects of teriparatide, may be of greater concern in persons with a SCID, although this is a greater concern immediately after injury, rather than with chronic SCID.\(^{[50–52]}\)

This work has a number of important strengths. To start, to our knowledge, our cohort of more than 100 fracture nonunions is larger than any prior description of fracture nonunions in persons with a SCID.\(^{[5,4]}\) Furthermore, by linkage to pharmacy records, we were able to examine the relationship of medication use to fracture nonunions in persons with SCID, which has not previously been reported. This is the first report to systematically examine complications of fracture nonunions and current treatment patterns for these nonunions in persons with a SCID.

There are also several limitations to consider. In clinical practice, there is considerable variability as to what is considered a nonunion, with definitions of nonunion ranging from 2 to 12 months post fracture.\(^{[53]}\) Radiographs were not uniformly available for review; thus, OTA fracture classification was not available.\(^{[54]}\) Potentially important modifiable predictors including smoking\(^{[23]}\) and alcohol use\(^{[20]}\) were not available for the nonunion controls, as all their information was obtained solely from administrative databases. ICD-9 codes, which were utilized in these analyses, do not include information on whether the fracture was comminuted or not. Gardner classification, which has been reported to be associated with fracture nonunion in SCID,\(^{[4]}\) was not available. Few patients underwent surgical treatment for their fracture and there may have been important differences in the association of fracture treatment (operative versus nonoperative) with the development of fracture nonunion for which we were underpowered. Additionally, while fracture nonunion in the able-bodied population is associated with pain and delay in returns to work,\(^{[7]}\) we did not examine functional outcomes of nonunion in this study, including whether outcomes differed by ambulatory status. Future studies should examine how functional outcomes of nonunion may differ between persons with a SCI who are partially ambulatory and those who are non-ambulatory. Regarding the relationship of medication use to nonunion, “use” of medications only represented filled prescriptions and not whether the patient actually took the medication and/or took it correctly, which is especially relevant to bisphosphonates. Because of the small number of filled prescriptions for anticoagulants other than warfarin, we were unable to examine the association of specific DOACs with the development of fracture nonunion. The association between
fracture characteristics, in particular open versus closed fractures as a risk factor for fracture nonunion, deserves further study. Although it is more likely that the unknown fractures were closed rather than open fractures as lower extremity fractures in SCID are most commonly from low or no impact trauma, if this was not the case, then open fractures would have been a significant risk factor for fracture nonunion in these analyses. Finally, we did not have information on stage of pressure injury.

In conclusion, older age and longer duration of SCID are key risk factors for the development of fracture nonunion in persons with a SCID. The distal femur is the most common lower extremity fracture site to develop a fracture nonunion. In view of the serious complications of these nonunions, targeted interventions in these high-risk individuals who have any signs of delayed union should be considered.

Disclosures

All authors state that they have no conflicts of interest.

Acknowledgments

This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development and Health Services Research and Development, VA IIR 15-294: Best Practices for Management of Fractures in Spinal Cord Injuries and Disorders. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.

Authors’ roles: BS: data curation, investigation, writing—original draft. CR: data curation, methodology, writing—original draft, writing—review and editing. FW: conceptualization, supervision, data curation, funding acquisition, formal analysis, methodology, writing—review and editing. BG: data curation, formal analysis, methodology, writing—review and editing. EC: data curation, writing—review and editing. SP: data curation, writing—review and editing. MR: data curation, writing—review and editing. RE: data curation, writing—original draft. SM: data curation, methodology, writing—review and editing. EC: conceptualization, data curation, formal analysis, funding acquisition, methodology, writing—original draft.

Peer Review

The peer review history for this article is available at https://publons.com/publon/10.1002/jbm4.10595.

Data Availability Statement

The data that support the findings of this study are the property of the United States Government’s Department of Veterans Affairs (VA) and are only available as part of VA-approved research activities pursuant to VHA Directives 1200.05 (2), VHA 1200.01, and/or VHA 1080.01.

References

1. Gifre L, Vidal J, Carrasco J, et al. Incidence of skeletal fractures after traumatic spinal cord injury: a 10-year follow-up study. Clin Rehabil. 2014;28(4):361-369.

2. Zehnder Y, Luthi M, Michel D, et al. Long-term changes in bone metabolism, bone mineral density, quantitative ultrasound parameters, and fracture incidence after spinal cord injury: a cross-sectional observational study in 100 paraplegic men. Osteoporos Int. 2004;15(3):180-189.

3. Morse LR, Battaglino RA, Stolzmann KL, et al. Osteoporotic fractures and hospitalization risk in chronic spinal cord injury. Osteoporos Int. 2009;20(3):385-392.

4. Grassner L, Klein B, Maier D, Bühren V, Vogel M. Lower extremity fractures in patients with spinal cord injury characteristics, outcome and risk factors for non-unions. J Spinal Cord Med. 2018;41(6):676-683.

5. Richards CJ, Graf KW Jr, Mashru RP. The effect of opioids, alcohol, and nonsteroidal anti-inflammatory drugs on fracture union. Orthop Clin North Am. 2017;48(4):433-443.

6. Bethel M, Bailey L, Weaver F, et al. Surgical compared with nonsurgical management of fractures in male veterans with chronic spinal cord injury. Spinal Cord. 2015;53(5):402-407.

7. Tay WH, de Steiger R, Richardson M, Gruen R, Balogh ZJ. Health outcomes of delayed union and nonunion of femoral and tibial shaft fractures. Injury. 2014;45(10):1633-1658.

8. Patzakis MJ, Zalavras CG. Chronic posttraumatic osteomyelitis and infected nonunions of the tibia: current management concepts. J Am Acad Orthop Surg. 2005;13(6):417-427.

9. Lala D, Dumont FS, Leblond J, Houghton PE, Noreau L. Impact of pressure ulcers on individuals living with a spinal cord injury. Spinal Cord Med Rehabil. 2014;95(12):2312-2319.

10. Verdonk R, Goubau Y, Almqvist FK, Verdonk P. Biological methods to enhance bone healing and fracture repair. Arthroscopy. 2015;31(4):715-718.

11. Papanagiotou M, Dailiana ZH, Karachalios T, et al. RbMP-7 for the treatment of nonunion of fractures of long bones. Bone Jt J. 2015;97-b(7):997-1003.

12. Ryan Martin J, Westermark G, Mullis B, Anglen J. A retrospective comparative analysis of the use of implantable bone stimulators in nonunions. J Surg Orthop Adv. 2017;26(3):128-133.

13. Xiaofeng L, Daxia X, Yunzhen C. Teriparatide as a nonoperative treatment for tibial and femoral fracture nonunion: a case report. Medicine. 2017;96(16):e6571.

14. Davda K, Heidari N, Calder P, Goodier D. ‘Rail and nail’ bifocal management of atrophic femoral nonunion. Bone Jt J. 2018;100-b(5):634-639.

15. Smith BM, Evans CT, Ullrich P, et al. Using VA data for research in persons with spinal cord injuries and disorders: lessons from SCI QUERI. J Rehabil Res Dev. 2010;47(8):679-688.

16. Logan WC Jr, Sloane R, Lyles KW, Goldstein B, Hoening HM. Incidence of fractures in a cohort of veterans with chronic multiple sclerosis or traumatic spinal cord injury. Arch Phys Med Rehabil. 2008;89(2):237-243.

17. Zura R, Braid-Forbes MJ, Jeray K, et al. Bone fracture nonunion rate decreases with increasing age: a prospective inception cohort study. Bone. 2017;95:26-32.

18. Zura R, Watson JT, Einhorn T, et al. An inception cohort analysis to predict nonunion in tibia and 17 other fracture locations. Injury. 2017;48(6):1194-1203.

19. Westgeest J, Weber D, Dulai SK, Bergman JW, Buckley R, Beaufre LA. Factors associated with development of nonunion or delayed healing after an open long bone fracture: a prospective cohort study of 736 subjects. J Orthop Trauma. 2016;30(3):149-155.

20. Zura R, Xiong Z, Einhorn T, et al. Epidemiology of fracture nonunion in 18 human bones. JAMA Surg. 2016;151(11):e162775.

21. Mitani Y. Effective treatment of a steroid-induced femoral neck fracture nonunion with a once-weekly administration of teriparatide in a rheumatoid patient: a case report. Arch Orthop Res. 2013;8:131.

22. Metsemakers WJ, Roels N, Belmans A, Reyners P, Nijs S. Risk factors for nonunion after intramedullary nailing of femoral shaft fractures: remaining controversies. Injury. 2015;46(6):1601-1607.

23. Santolíni E, West R, Giannoudis PV. Risk factors for long bone fracture non-union: a stratification approach based on the level of the existing scientific evidence. Injury. 2015;46(Suppl 8):S58-S59.
24. Yokoyama S, Ieda S, Nagano M, et al. Association between oral anti-coagulants and osteoporosis: real-world data mining using a multi-methodological approach. Int J Med Sci. 2020;17(4):471-479.
25. Tamblyn R, Bates DW, Buckeridge DL, et al. Multinational investigation of fracture risk with antidepressant use by class, drug, and indication. J Am Geriatr Soc. 2020;68(7):1494-1503.
26. Bethel M, Weaver FM, Bailey L, et al. Risk factors for osteoporotic fractures in persons with spinal cord injuries and disorders. Osteoporos Int. 2016;27(10):3011-3021.
27. Carbone LD, Chin AS, Lee TA, et al. The association of opioid use with incident lower extremity fractures in spinal cord injury. J Spinal Cord Med. 2013;36(2):91-96.
28. George MD, Baker JF, Leonard CE, Mehta S, Miano TA, Hennessy S. Risk of nonunion with nonselective NSAIDs, COX-2 inhibitors, and opioids. J Bone Joint Surg Am. 2020;102(14):1230-1238.
29. Buchheit T, Zura R, Wang Z, Mehta S, Della Rocca GJ, Steen RG. Opioid exposure is associated with nonunion risk in a traumatically injured population: an inception cohort study. Injury. 2018;49(7):1266-1271.
30. Battaglino RA, Lazzari AA, Garshick E, Morse LR. Spinal cord injury-induced osteoporosis: pathogenesis and emerging therapies. Curr Osteoporos Rep. 2012;10(4):278-285.
31. Goltzman D. The aging skeleton. Adv Exp Med Biol. 2013;764:153-160.
32. Gong HS, Song CH, Lee YH, Rhee SH, Lee HJ, Baek GH. Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures. J Bone Joint Surg Am. 2012;94(19):1729-1736.
33. Rozental TD, Vazquez MA, Chacko AT, Ayogu N, Bouxsein ML. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg Am. 2009;34(4):595-602.
34. Molvik H, Khan W. Bisphosphonates and their influence on fracture healing: a systematic review. Osteoporos Int. 2015;26(4):1251-1260.
35. Kates SL, Ackert-Bicknell CL. How do bisphosphonates affect fracture healing? Injury. 2016;47(1):565-568.
36. Li YT, Cai HF, Zhang ZL. Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2015;26(2):431-441.
37. Be B, Ray C, Gonzalez B, et al. Reasons for initiation and discontinuation of pharmacological therapies of osteoporosis in veterans with spinal cord injury and disorders. J Clin Densitom. 2021;24(1):67-77.
38. Froitzler A, Cheikh-Sarraf B, Pourtehrani M, Krebs J, Lippuner K. Long bone fractures in persons with spinal cord injury. Spinal Cord. 2015;53(9):701-704.
39. Regan MA, Teasell RW, Wolfe DL, Keast D, Mortenson WB, Aubut JA. A systematic review of therapeutic interventions for pressure ulcers after spinal cord injury. Arch Phys Med Rehabil. 2009;90(2):213-231.
40. Krause JS, Carter RE, Pickelsimer EE, Wilson D. A prospective study of health and risk of mortality after spinal cord injury. Arch Phys Med Rehabil. 2008;89(8):1482-1491.
41. Svircev J, Tan D, Garrison A, Pennelly B, Burns SP. Limb loss in individuals with chronic spinal cord injury. J Spinal Cord Med. 2020;1-6.
42. Dillingham TR, Pezzin LE, MacKenzie EJ. Limb amputation and limb deficiency: epidemiology and recent trends in the United States. South Med J. 2002;95(8):875-883.
43. Low EE, Inkellis E, Morshed S. Complications and revision amputation following trauma-related lower limb loss. Injury. 2017;48(2):364-370.
44. Sontich JK, Zalavras CG, Marcus RE. Secrets of success in the management of lower extremity nonunions. Instr Course Lect. 2021;70:163-180.
45. Rupp M, Blehl C, Budak M, Thomann U, Heiss C, Alt V. Diaphyseal long bone nonunions—types, aetiology, economics, and treatment recommendations. Int Orthop. 2018;42(2):247-258.
46. Hak DJ. Management of aseptic tibial nonunion. J Am Acad Orthop Surg. 2011;19(9):563-573.
47. Lynch JR, Taitsman LA, Barel DP, Nork SE. Femoral nonunion: risk factors and treatment options. J Am Acad Orthop Surg. 2008;16(2):88-97.
48. Busse JW, Bhandari M. Therapeutic ultrasound and fracture healing: a survey of beliefs and practices. Arch Phys Med Rehabil. 2004;85(10):1653-1656.
49. Ciurlia E, Leali PT, Doria C. Use of teriparatide off-label: our experience and review of literature. Clin Cases Miner Bone Metab. 2017;14(1):28-34.
50. Maynard FM, Imai K. Immobilization hypercalcemia in spinal cord injury. Arch Phys Med Rehabil. 1977;58(1):16-24.
51. Maynard FM. Immobilization hypercalcemia following spinal cord injury. Arch Phys Med Rehabil. 1986;67(1):41-44.
52. Naftchi NE, Viau AT, Sell GH, Lowman EW. Mineral metabolism in spinal cord injury. J Am Acad Orthop Surg. 2007;15(9):562-566.
53. Marsh JL, Slongo TF, Age J, et al. Fracture and dislocation classification compendium—2007: orthopaedic trauma association classification, database and outcomes committee. J Orthop Trauma. 2007;21(10 Suppl):S1-S133.